Clinical Trials Logo

Filter by:
  • Recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06377592 Recruiting - Clinical trials for Bacterial Infections

Development and Accuracy Evaluation of Gram Staining Analysis AI

Start date: May 10, 2023
Phase:
Study type: Observational

The investigators use Gram-stained specimens provided from clinical settings to develop and evaluate the accuracy of Gram staining analysis AI

NCT ID: NCT06372613 Recruiting - Clinical trials for Ulcerative Colitis in Remission

Association Between LRG and Endoscopic Remission in Ulcerative Colitis

Start date: February 25, 2024
Phase:
Study type: Observational

We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which predicts endoscopic remission in ulcerative colitis patients in this study. Colonoscopy with histology is performed when endoscopic remission will be predicted based on serum LRG values, irrespective of symptoms. Serum LRG levels were analyzed by an enzyme-linked immunosorbent assay.

NCT ID: NCT06362044 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Start date: June 7, 2023
Phase:
Study type: Observational

Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan. Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be enrolled in the study in sites in Japan. Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab treatments for CLL according to the approved local label. The overall study duration will be 27 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.

NCT ID: NCT06361433 Recruiting - Clinical trials for Intracerebral Hemorrhage

Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage

RAINBOW-Hx
Start date: December 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to test intracerebral transplantation of stem cell product in patient with chronic intracerebral hemorrhage. The main questions aims to answer are: - The safety of the product - The efficacy of the product

NCT ID: NCT06355934 Recruiting - ATTR Amyloidosis Clinical Trials

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

OverTTuRe
Start date: August 21, 2023
Phase:
Study type: Observational

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.

NCT ID: NCT06346392 Recruiting - Gastric Cancer Clinical Trials

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Start date: March 4, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

NCT ID: NCT06342440 Recruiting - Colorectal Cancer Clinical Trials

Early Detection of Advanced Adenomas and Colorectal Cancer

AACRC
Start date: March 15, 2020
Phase:
Study type: Observational

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

NCT ID: NCT06342427 Recruiting - Gastric Cancer Clinical Trials

Stomach Cancer Exosome-based Detection

DESTINEX
Start date: March 15, 2023
Phase:
Study type: Observational

Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.

NCT ID: NCT06342414 Recruiting - Clinical trials for Hepatocellular Carcinoma

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

ELUCIDATE
Start date: March 15, 2024
Phase:
Study type: Observational

It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.

NCT ID: NCT06342401 Recruiting - Colorectal Cancer Clinical Trials

Early Onset Colorectal Cancer Detection

ENCODE
Start date: April 15, 2023
Phase:
Study type: Observational

Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women. This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid)